Beam therapeutics inc. BEAM.US Overview
BEAM AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
BEAM Current Performance
1.10%
Beam therapeutics inc.
-0.91%
Avg of Sector
-0.13%
S&P500
BEAM Key Information
BEAM Revenue by Segments
Browsing restrictions can be lifted for a fee.
BEAM Net Income
Browsing restrictions can be lifted for a fee.
BEAM Cash Flow
Browsing restrictions can be lifted for a fee.
BEAM Profit Margin
Browsing restrictions can be lifted for a fee.
BEAM PE Ratio River
Browsing restrictions can be lifted for a fee.
BEAM Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
BEAM Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
BEAM Profile
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Price of BEAM
BEAM FAQ
When is BEAM's latest earnings report released?
The most recent financial report for Beam therapeutics inc. (BEAM) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BEAM's short-term business performance and financial health. For the latest updates on BEAM's earnings releases, visit this page regularly.
What is the operating profit of BEAM?
According to the latest financial report, Beam therapeutics inc. (BEAM) reported an Operating Profit of -119.29M with an Operating Margin of -1,596.87% this period, representing a decline of 14.55% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is BEAM's revenue growth?
In the latest financial report, Beam therapeutics inc. (BEAM) announced revenue of 7.47M, with a Year-Over-Year growth rate of 0.81%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does BEAM have?
As of the end of the reporting period, Beam therapeutics inc. (BEAM) had total debt of 158.13M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does BEAM have?
At the end of the period, Beam therapeutics inc. (BEAM) held Total Cash and Cash Equivalents of 534.52M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does BEAM go with three margins increasing?
In the latest report, Beam therapeutics inc. (BEAM) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,596.87%%, and net margin of -1,462.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BEAM's profit trajectory and future growth potential.
Is BEAM's EPS continuing to grow?
According to the past four quarterly reports, Beam therapeutics inc. (BEAM)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of BEAM?
Beam therapeutics inc. (BEAM)'s Free Cash Flow (FCF) for the period is -106.95M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 4.66% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of BEAM?
The latest valuation data shows Beam therapeutics inc. (BEAM) has a Price-To-Earnings (PE) ratio of -4.15 and a Price/Earnings-To-Growth (PEG) ratio of -0.29. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.